Found 6 matches for
Byline: Andrew Pollard and Katherine Theiss-Nyland, Oxford Vaccine Group, Oxford University
COVID-19 Publication Research
17 December 2020
Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
14 November 2020
Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
24 June 2019
PBS features Daniel O'Connor's research on how children's genetic profiles affect their immunity.
Awards & Appointments Publication Research
28 February 2018
Mildred Iro, a Paediatric Research Fellow working with the Oxford Vaccine Group, won the Lorber Prize for the best paediatric publication of 2017 for her work on childhood encephalitis admissions.